JPRN-C000000405已完成3 期
Randomized, double-blind, placebo-controlled multi center clinical trial for the prevention of chronic lung disease in extremely low birth weight infants with inhaled fluticasone propionate - Randomized, double-blind, multi center clinical trial for the prevention of chronic lung disease in extremely low birth weight infants with inhaled fluticasone propionate
eonatal Research Network Japan0 个研究点目标入组 211 人开始时间: 2006年4月12日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 211
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 0weeks-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Subjects with sepsis, pneumonia or severe acute infection (2)Subjects with severe liver dysfunction. (3)Subjects with suspected immunodeficiency or abnormal adrenal function. (4)Subjects with uncontrollable hyperglycemia (5)Subjects with uncontrollable hypertension (6)Subjects with severe malformation, highly suspected chromosomal abnormality (7)Subjects with renal dysfunction. (8)Subjects judged by the investigator to be inappropriate as study subjects.
研究者
相似试验
进行中（未招募）
不适用
In this clinical study, a new drug, Budesonid 3 mg effervescent tablet for the preparation of a mouth rinse solution to treat oral chronic GvHD (Graft versus Host Disease) resulting from allogeneic (taken from different individuals of the same species) haematopoietic (blood cell forming) stem cell transplantation (HSCT), is evaluated.Oral chronic graft versus host disease as a complication of haematopoietic stem cell transplantation.MedDRA version: 16.0Level: PTClassification code 10066261Term: Chronic graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2008-004562-10-CZDr. Falk Pharma GmbH224
进行中（未招募）
不适用
In this clinical study, a new drug, Budesonid 3 mg effervescent tablet for the preparation of a mouth rinse solution to treat oral chronic GvHD (Graft versus Host Disease) resulting from allogeneic (taken from different individuals of the same species) haematopoietic (blood cell forming) stem cell transplantation (HSCT), is evaluated.Oral chronic graft versus host disease as a complication of haematopoietic stem cell transplantation.MedDRA version: 14.1Level: PTClassification code 10066261Term: Chronic graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2008-004562-10-SEDr. Falk Pharma GmbH224
进行中（未招募）
1 期
Double-blind, randomised, placebo-controlled multicentre phase III clinical study followed by open-label phase on the efficacy and tolerability of budesonide 3 mg effervescent tablet in patients with resistant oral chronic GvHDOral chronic graft versus host disease as a complication of haematopoietic stem cell transplantation.MedDRA version: 9.1Level: LLTClassification code 10066261Term: Chronic graft versus host diseaseEUCTR2008-004562-10-FRDr. Falk Pharma GmbH126
进行中（未招募）
不适用
Double-blind, randomised, placebo-controlled multicentre phase III clinical study followed by open-label phase on the efficacy and tolerability of budesonide 3 mg effervescent tablet in patients with resistant oral chronic GvHD - NDChronic Graft versus Host DiseaseMedDRA version: 12.1Level: LLTClassification code 10066261Term: Chronic graft versus host diseaseEUCTR2008-004562-10-ITDR. FALK PHARMA GMBH126
进行中（未招募）
不适用
In this clinical study, a new drug, Budesonid 3 mg effervescent tablet forthe preparation of a mouth rinse solution to treat oral chronic GvHD(Graft versus Host Disease) resulting from allogeneic (taken fromdifferent individuals of the same species) haematopoietic (blood cellforming) stem cell transplantation (HSCT), is evaluated.Oral chronic graft versus host disease as a complication of haematopoietic stem cell transplantation.MedDRA version: 17.1Level: PTClassification code 10066261Term: Chronic graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2008-004562-10-ATDr. Falk Pharma GmbH224